Activation of Fc receptor-bearing lymphocytes by immune complexes. II. Killer lymphocytes mediate Fc ligand-induced lymphokine production

Ligand binding but undetected functional response of FcR after their capture by T cells via trogocytosis

Intercellular transfer of cell surface proteins by trogocytosis is common and could affect T cell responses. Yet, the role of trogocytosis in T cell function is still elusive, and it is unknown whether a molecule, once captured by T cells, harbors the same biological properties as in donor APC. In this study, we showed that FcgammaR as well as the associated FcRgamma subunit could be detected at high levels on murine and human T cells after their intercellular transfer from FcgammaR-expressing APC. Capture of FcgammaR occurred during coculture of T cells with FcgammaR-expressing APC upon Ab- or Ag-mediated T cell stimulation. Once captured by T cells, FcgammaR were expressed in a conformation compatible with physiological function and conferred upon T cells the ability to bind immune complexes and to provision B cells with this source of Ag. However, we were unable to detect downstream signal or signaling-dependent function following the stimulation of FcgammaR captured by T cells, and biochemical studies suggested the improper integration of FcgammaR in the recipient T cell membrane. Thus, our study demonstrates that T cells capture FcgammaR that can efficiently exert ligand-binding activity, which, per se, could have functional consequences in T cell-B cell cooperation.

The effect of synthetic peptides corresponding to Fc sequences in human IgG1 on various steps in the B cell activation pathway

The influence of synthetic peptides comprising sequences in the exposed positions of the Fc region of human IgG 1 was tested on B lymphocyte activation. CH 2 domain peptides having an inhibitory effect on antibody-dependent cellular cytotoxicity, as well as the whole Fc fragment, induced the appearance of the early signs of activation on resting B lymphocytes such as increase in cell volume and HLA-DR antigen expression or leukocyte migration inhibitory factor production. The peptides did not induce proliferation of resting B cells even when B cell growth factor (BCGF)-containing supernatants were added. Exposure to Fc fragment, however, induced a weak proliferation which was significantly enhanced by BCGF. On the other hand, both the Fc fragment and the CH 2 or CH 3 domain peptides enhanced the IgM synthesis of human blood mononuclear cells when a suboptimal dose of pokeweed mitogen was present. This effect was lost when Fc fragment or the peptides were added on the third day of culture. These results suggest that the early steps of B cell activation can be induced by Fc fragment and by small molecular weight Fc peptides, which are potential ligands of Fc receptors. The Fc fragment activates B cells to the state where they respond to BCGF, but the peptides do not possess this activity. Furthermore, both Fc fragment and Fc peptides are able to enhance the IgM synthesis, when accessory cells and the appropriate differentiating factors are present.

A novel lymphokine derived from human IgG Fc receptor-bearing B cells: its suppressive effect on activated T and B lymphocytes including tumour cells in vitro

Peripheral blood FcR gamma-bearing human B cells, but neither T cells nor adherent cells, produce an immunoregulatory lymphokine after receiving the stimulation of FcR gamma by immune complexes--antibody-sensitized erythrocytes (EA). This factor suppresses polyclonal immunoglobulin (Ig) production of B cells to pokeweed mitogen (PWM) and Nocardia opaca delipidated cell mitogen (NDCM), indicating that not only B cells, but also T cells are targets for this factor. It also inhibits the proliferation of mitogen-activated mononuclear and T and B tumour cells in vitro. The inhibitory effect on tumour cell growth is cytostatic, but not cytotoxic as in the case of lymphotoxin (LT). All these suppressive effects are observed in a HLA-non-restricted manner. Irradiation (2000 rads) of FcR gamma + B cells does not inhibit the production of this suppressive factor, implying that DNA synthesis is unnecessary. Nonstimulated FcR gamma + B cells retain the precursor activity for Ig-forming cells, since mononuclear cells untreated with EA respond to the mitogens, resulting in Ig production. However, it is worthy to note that they lose the activity when stimulated with immune complexes. Thus, the property obtained from human FcR gamma + B cells is similar to, but distinct from, a murine suppressive B-cell factor (SBF) prepared by the same procedure as for the human factor. Nevertheless, the observation in the present studies on the human analogue to murine SBF suggests that this factor, tentatively termed human SBF, appears to be a novel lymphokine which is different from any other factors, including LT, and that FcR-bearing B cells play an important role in the immunoregulatory mechanism in humans, as in the case of mice.

Antibody- and interferon-dependent killer cells are part of the NK cell receptor positive subpopulation of human peripheral blood cells

Cytotoxicity by human non-adherent peripheral blood lymphocytes was analysed after effector cell activation with either interferon (IF) or by target cell specific IgG antibodies (T-IgG). Four different cell lines were used as target cells that differed in susceptibility to natural killer cell (NK) activity; a highly susceptible T cell line (Molt-4), a medium susceptible B lymphoma line (Daudi), a resistant B cell line established by Epstein-Barr virus transformation (LCL-LS) and a resistant mouse mastocytoma line (P815). Three different parameters influencing killing were investigated; lytic potential, target cell binding and efficiency of the lytic phase from which the absolute number of effector cells and their recycling capacity could be estimated. It was found that, when using human target cell lines, IF and T-IgG influenced the system in a similar way by activating the lytic phase and the effector cell recycling but not the early binding phase. With the NK resistant mouse mastocytoma cell line P815 a comparatively small target binding population was found which, however, increased markedly with T-IgG treatment. Taken together, the results indicate that the effector population responsible for antibody-induced killing belong to a subpopulation of cells that have the ability to spontaneously conjugate to the present target cells by virtue of naturally occuring undefined cell surface receptors designated NKR (NK receptor) and that the role of T-IgG in the present system is similar to that of IF. In contrast, if target cells are used that do not express binding structures for NKR receptors, T-IgG may also fulfill a receptor function through Fc receptors for IgG.

Case for adoptive immunotherapy in cancer

Patients with normal immune systems may be unable to mount effective defences against solid tumours because of (1) the generation of suppressor T cells in the low zone tolerance response elicited by the low concentrations of antigen furnished by slow growing solid tumours; (2) the ineffectiveness of the cytolytic T-cell response when the tumour cell membrane lacks the major histocompatibility gene products required for linkage to tumour antigens; and (3) the hindrance of antibody-dependent cellular cytotoxicity by antitumour antibodies when the precise requirements for the reaction cannot be fulfilled in the sites occupied by solid tumours. Recent immunological advances suggest that it should be possible to isolate antigens from cancer cells, produce antibodies against these antigens, bind the antibodies to the patient's macrophages and K lymphocytes, and reinject the bound cells into the patients to stimulate lymphokine synthesis and antibody-dependent cellular cytoxicity.

Cell-mediated immunity and immune complexes in the pathogenesis of type 1 (insulin-dependent) diabetes

Evidence for a role of the immune system in the pathogenesis of insulin-dependent (Type 1) diabetes is now plentiful. In the light of the lymphocytic infiltration in the islets of Langerhans, different autoaggressive mechanisms have been suggested in the initiation of B-cell damage. Lymphocytes characterized by cytotoxic properties (K cells) and having receptors for the Fc of IgG are increased in newly diagnosed Type 1 diabetics. Circulating immune complexes are also raised in these patients at the time of clinical diagnosis and there is evidence that K cells bind immune complexes which can modulate the activity of these cells. Here we propose a possible interrelationship between K or Fc gamma receptor+ T lymphocytes and immune complexes which could have a 'key' role in the mechanism of activation of cell-mediated immunity towards B-cells.